Literature DB >> 2530248

Biochemical basis of synergy between antigen and T-helper (Th) cell-mediated activation of resting human B cells.

E K Chartash1, M K Crow, S M Friedman.   

Abstract

We have utilized CD23 expression as a marker for B cell activation in order to investigate the biochemical basis for synergy between antigen and T helper (Th) cells in the activation of resting human B cells. Our results confirm that while ligation of surface immunoglobulin (sIg) receptors by antigen analogues (e.g., F(ab')2 goat anti-human IgM) does not lead to CD23 expression, this stimulus markedly enhances CD23 expression induced during antigen specific Th-B cell interaction or by rIL-4. Utilizing a panel of monoclonal anti-human IgM antibodies, we observed a positive correlation between the capacity of a particular antibody to synergize with rIL-4 in CD23 expression and with B cell growth factor in B cell proliferation; suggesting that synergy in CD23 expression reflects the transduction of a functionally important signal via the sIg receptor. We next assayed analogues of the "second messenger" molecules, released during inositol lipid hydrolysis, for their capacity to amplify CD23 expression. These studies showed that protein kinase C (PKC) activating phorbol esters and the synthetic diacylgylcerol analogue, DiC8, synergize with either Th cells or rIL-4 in CD23 expression, while under no experimental condition does increasing B cell [Ca2+]i with ionomycin enhance CD23 expression. Taken together, these data suggest that activation of B cell PKC is the crucial biochemical event that primes antigen-activated B cells to respond more vigorously to interaction with Th cells and/or their soluble products.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530248      PMCID: PMC304003          DOI: 10.1172/JCI114314

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

Review 1.  The role of phosphoinositides in signal transduction.

Authors:  M C Sekar; L E Hokin
Journal:  J Membr Biol       Date:  1986       Impact factor: 1.843

2.  Activated B lymphocytes: stimulators of an augmented autologous mixed leukocyte reaction.

Authors:  M K Crow; H G Kunkel
Journal:  Cell Immunol       Date:  1985-02       Impact factor: 4.868

3.  B lymphocyte receptors and polyphosphoinositide degradation.

Authors:  M K Bijsterbosch; C J Meade; G A Turner; G G Klaus
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

4.  Cloned allospecific human helper T cell lines induce an MHC-restricted proliferative response by resting B cells.

Authors:  D Goldberg; A Green; A B Gottlieb; M K Crow; A Lewison; S M Friedman
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

5.  Allospecific human T cell lines and clones which mediate HLA-DR restricted helper activity.

Authors:  S M Friedman; G S Thompson; M A Principato
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

Review 6.  Activation of plasma membrane phosphatidylinositol turnover by hormones.

Authors:  J N Fain
Journal:  Vitam Horm       Date:  1984       Impact factor: 3.421

Review 7.  Inositol trisphosphate, a novel second messenger in cellular signal transduction.

Authors:  M J Berridge; R F Irvine
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

8.  B cell activation. VIII. Membrane immunoglobulins transduce signals via activation of phosphatidylinositol hydrolysis.

Authors:  K M Coggeshall; J C Cambier
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

9.  Differential sensitivity of human B cell subsets to activation signals delivered by anti-mu antibody and proliferative signals delivered by a monoclonal B cell growth factor.

Authors:  A Muraguchi; J L Butler; J H Kehrl; A S Fauci
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

10.  Human B cell activation. Evidence for diverse signals provided by various monoclonal anti-IgM antibodies.

Authors:  S M Rudich; R Winchester; P K Mongini
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.